CHU Montpellier, Université de Montpellier, Unité d'Endocrinologie-Gynécologie Pédiatrique, Service de Pédiatrie, 34295 Montpellier, France.
CHU Montpellier, Université de Montpellier, Centre de Référence Maladies Rares du Développement Génital, Constitutif Sud, Hôpital Lapeyronie, 34295 Montpellier, France.
Int J Environ Res Public Health. 2023 Jan 31;20(3):2542. doi: 10.3390/ijerph20032542.
Diethylstilbestrol (DES), a potent synthetic nonsteroidal estrogen belonging to the family of endocrine disrupting chemicals (EDCs), can cross the placenta and may cause permanent adverse health effects in the exposed mothers, their children (exposed in utero), and also their grandchildren through germline contribution to the zygote. This study evaluated pregnancy duration and birthweight (BW) variations in the children and grandchildren born before, during, and after maternal DES treatment in the same informative families, to rule out genetic, endocrine, and environmental factors.
Nationwide retrospective observational study on 529 families of DES-treated women registered at the HHORAGES-France Association. The inclusion criteria were: (i) women with at least three pregnancies and three viable children among whom the first was not exposed in utero to DES, followed by one or more children with fetal exposure to DES, and then by one or more children born after DES treatment; (ii) women with at least one pre-DES or post-DES grandchild and one DES grandchild; (iii) confirmed data on total DES dose. Women with severe pathologies or whose illness status, habitat, lifestyle habits, profession, treatment changed between pregnancies, and all mothers who reported pregnancy-related problems, were excluded.
In all, 74 women met all criteria. The preterm birth (PTB) rate was 2.7% in pre-DES, 14.9% in DES, and 10.8% in post-DES children (Cochran-Armitage test for trend, = 0.0095). The mean BW was higher in DES than pre-DES full-term neonates (≥37 weeks of gestation) ( = 0.007). In grandchildren, BW was not different, whereas the PTB and low BW rates were slightly increased in children of DES women.
These data within the same informative families show the DES impact on BW and PTB in DES and post-DES children and grandchildren. In particular, mean BW was higher in DES than pre-DES full-term neonates. This result may be in opposition to previous data from American cohorts, which reported lower BW in DES children, but is consistent with animal study. Our retrospective observational study highlights a multigenerational and likely transgenerational effect of this EDC in humans.
己烯雌酚(DES)是一种强效合成非甾体雌激素,属于内分泌干扰化学物质(EDCs)家族,可穿过胎盘,并可能对暴露于该物质的母亲、其胎儿(宫内暴露)以及通过种系传递给受精卵的孙子孙女造成永久性不良健康影响。本研究在相同的信息家族中,评估了在母亲接受 DES 治疗之前、期间和之后出生的儿童和孙辈的妊娠持续时间和出生体重(BW)变化,以排除遗传、内分泌和环境因素的影响。
在 HHORAGES-France 协会注册的 529 名接受 DES 治疗的女性的全国性回顾性观察性研究。纳入标准为:(i)至少有三次妊娠和三个活产儿的女性,其中第一个胎儿未在宫内接触 DES,随后有一个或多个胎儿接触 DES,然后有一个或多个胎儿在 DES 治疗后出生;(ii)至少有一个 DES 前或 DES 后孙辈和一个 DES 孙辈;(iii)确认 DES 总剂量的数据。患有严重疾病或疾病状态、居住地、生活方式习惯、职业、治疗方法在妊娠期间发生变化的所有女性以及所有报告妊娠相关问题的母亲均被排除在外。
共有 74 名女性符合所有标准。DES 前、DES 和 DES 后儿童的早产(PTB)率分别为 2.7%、14.9%和 10.8%(Cochran-Armitage 趋势检验, = 0.0095)。DES 足月新生儿(≥37 周妊娠)的平均 BW 高于 DES 前组( = 0.007)。在孙辈中,BW 没有差异,而 DES 女性的儿童中 PTB 和低 BW 率略有增加。
在相同的信息家族中,这些数据显示 DES 对 DES 和 DES 后儿童和孙辈的 BW 和 PTB 有影响。特别是,DES 组的平均 BW 高于 DES 前组的足月新生儿。这一结果可能与之前美国队列报告的 DES 儿童 BW 较低的数据相矛盾,但与动物研究结果一致。我们的回顾性观察性研究强调了这种内分泌干扰物在人类中具有多代和可能跨代的影响。